Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of LY3202328
NCT02714569Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3202328 in dyslipidemia (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration up to 42 Days. Started Mar 2016; status: completed.
02
Drugs
LY3202328
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02714569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02714569.